All In Biotech

NDA 020547 · Strides Pharma Intl

Accolate

Zafirlukast · Oral · Leukotriene Receptor Antagonist

Novel

Last checked: Nov 19, 2026Latest source record: Mar 29, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

Sep 26, 1996

Approved uses

3

Original approval plus efficacy supplements

Registered trials

6

1 Phase 3, 0 recruiting

FAERS reports

907

477 serious, 44 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 16, 2026.

INDICATIONS AND USAGE Zafirlukast is indicated for the prophylaxis and chronic treatment of asthma in adults and children 5 years of age and older.

Therapeutic areas: Respiratory

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 27, 2001 Supplement 14 · Efficacy Letter
  • Sep 17, 1999 Supplement 7 · Efficacy ReviewLetter
  • Sep 26, 1996 Original approval · Type 1 - New Molecular Entity Review
2 products under this application
  • ACCOLATE · ZAFIRLUKAST 10MG · TABLET, ORAL · Prescription · TE AB
  • ACCOLATE · ZAFIRLUKAST 20MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Zafirlukast" as an intervention, any sponsor and status, largest first.

All 6 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea110
  • asthma96
  • fatigue87
  • drug ineffective65
  • cough56
  • nausea51
  • pruritus49
  • off label use48
  • wheezing48
  • headache47
  • rash47
  • pneumonia46

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200418
200510
20067
20079
200813
200914
201015
201114
201227
201325
201432
201538
201677
201751
201860
201951
202064
202168
202256
202353
202467
202583
202655

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 100 on PubMed

Sponsor: Strides Pharma Intl

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.